Dariohealth Corp (DRIO)

$1.61

-0.02

(-1.23%)▲

Market is closed - opens 7 PM, 09 May 2024

Insights on Dariohealth Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 3.51M → 3.61M (in $), with an average increase of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 16.90M → -12.00M (in $), with an average decrease of 171.0% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 20.7% return, outperforming this stock by 76.5%

  • Vs TMO

    In the last 3 years, Dariohealth Corp has experienced a drawdown of -91.2%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 89.0%

Performance

  • $1.53
    $1.61
    $1.61
    downward going graph

    4.92%

    Downside

    Day's Volatility :4.92%

    Upside

    0.0%

    downward going graph
  • $0.68
    $4.58
    $1.61
    downward going graph

    57.76%

    Downside

    52 Weeks Volatility :85.15%

    Upside

    64.85%

    downward going graph

Returns

PeriodDariohealth CorpSector (Health Care)Index (Russel 2000)
3 Months
-15.98%
-1.1%
0.0%
6 Months
35.83%
11.2%
0.0%
1 Year
-55.83%
7.0%
0.8%
3 Years
-90.65%
14.9%
-22.1%

Highlights

Market Capitalization
43.9M
Book Value
$2.14
Earnings Per Share (EPS)
-1.93
PEG Ratio
0.0
Wall Street Target Price
5.67
Profit Margin
-292.0%
Operating Margin TTM
-389.57%
Return On Assets TTM
-32.51%
Return On Equity TTM
-86.04%
Revenue TTM
20.4M
Revenue Per Share TTM
0.72
Quarterly Revenue Growth YOY
-46.9%
Gross Profit TTM
14.0M
EBITDA
-51.1M
Diluted Eps TTM
-1.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.37
EPS Estimate Next Year
-0.87
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Dariohealth Corp(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 252.17%

Current $1.61
Target $5.67

Company Financials

FY18Y/Y Change
Revenue
7.4M
↑ 43.02%
Net Income
-17.8M
↑ 13.09%
Net Profit Margin
-240.78%
↑ 63.73%
FY19Y/Y Change
Revenue
7.6M
↑ 2.23%
Net Income
-17.8M
↓ 0.2%
Net Profit Margin
-235.04%
↑ 5.74%
FY20Y/Y Change
Revenue
7.6M
↑ 0.22%
Net Income
-29.0M
↑ 63.15%
Net Profit Margin
-382.62%
↓ 147.58%
FY21Y/Y Change
Revenue
20.5M
↑ 170.76%
Net Income
-76.8M
↑ 164.81%
Net Profit Margin
-374.21%
↑ 8.41%
FY22Y/Y Change
Revenue
27.7M
↑ 34.82%
Net Income
-62.2M
↓ 18.98%
Net Profit Margin
-224.88%
↑ 149.33%
FY23Y/Y Change
Revenue
20.4M
↓ 26.41%
Net Income
-54.9M
↓ 11.79%
Net Profit Margin
-269.56%
↓ 44.68%
Q3 FY22Q/Q Change
Revenue
6.6M
↑ 6.83%
Net Income
-16.7M
↓ 7.42%
Net Profit Margin
-252.7%
↑ 38.87%
Q4 FY22Q/Q Change
Revenue
6.8M
↑ 3.09%
Net Income
-12.6M
↓ 24.41%
Net Profit Margin
-185.3%
↑ 67.4%
Q1 FY23Q/Q Change
Revenue
7.1M
↑ 3.77%
Net Income
12.4M
↓ 198.34%
Net Profit Margin
175.6%
↑ 360.9%
Q2 FY23Q/Q Change
Revenue
6.2M
↓ 12.94%
Net Income
-16.6M
↓ 233.66%
Net Profit Margin
-269.59%
↓ 445.19%
Q3 FY23Q/Q Change
Revenue
3.5M
↓ 42.82%
Net Income
16.9M
↓ 201.92%
Net Profit Margin
480.5%
↑ 750.09%
Q4 FY23Q/Q Change
Revenue
3.6M
↑ 2.79%
Net Income
-12.0M
↓ 170.99%
Net Profit Margin
-331.88%
↓ 812.38%
FY18Y/Y Change
Total Assets
14.1M
↑ 102.52%
Total Liabilities
5.2M
↑ 71.22%
FY19Y/Y Change
Total Assets
24.6M
↑ 74.38%
Total Liabilities
5.7M
↑ 9.9%
FY20Y/Y Change
Total Assets
35.4M
↑ 44.11%
Total Liabilities
7.3M
↑ 27.86%
FY21Y/Y Change
Total Assets
100.8M
↑ 184.61%
Total Liabilities
15.2M
↑ 109.79%
FY22Y/Y Change
Total Assets
119.2M
↑ 18.28%
Total Liabilities
39.2M
↑ 157.47%
FY23Y/Y Change
Total Assets
96.4M
↓ 19.13%
Total Liabilities
38.2M
↓ 2.42%
Q3 FY22Q/Q Change
Total Assets
126.3M
↓ 8.01%
Total Liabilities
37.4M
↓ 0.79%
Q4 FY22Q/Q Change
Total Assets
119.2M
↓ 5.65%
Total Liabilities
39.2M
↑ 4.83%
Q1 FY23Q/Q Change
Total Assets
108.0M
↓ 9.38%
Total Liabilities
36.0M
↓ 8.2%
Q2 FY23Q/Q Change
Total Assets
117.2M
↑ 8.47%
Total Liabilities
38.8M
↑ 7.72%
Q3 FY23Q/Q Change
Total Assets
106.5M
↓ 9.09%
Total Liabilities
38.5M
↓ 0.74%
Q4 FY23Q/Q Change
Total Assets
96.4M
↓ 9.5%
Total Liabilities
38.2M
↓ 0.58%
FY18Y/Y Change
Operating Cash Flow
-11.5M
↑ 8.01%
Investing Cash Flow
6.0K
↓ 102.74%
Financing Cash Flow
18.7M
↑ 39.22%
FY19Y/Y Change
Operating Cash Flow
-15.7M
↑ 37.1%
Investing Cash Flow
-113.0K
↓ 1983.33%
Financing Cash Flow
25.2M
↑ 34.7%
FY20Y/Y Change
Operating Cash Flow
-17.7M
↑ 12.79%
Investing Cash Flow
-1.6M
↑ 1335.4%
Financing Cash Flow
27.5M
↑ 9.11%
FY21Y/Y Change
Operating Cash Flow
-50.4M
↑ 184.22%
Investing Cash Flow
-8.1M
↑ 401.48%
Financing Cash Flow
65.8M
↑ 138.73%
FY22Y/Y Change
Operating Cash Flow
-47.8M
↓ 5.09%
Investing Cash Flow
-573.0K
↓ 92.96%
Financing Cash Flow
61.9M
↓ 5.82%
Q3 FY22Q/Q Change
Operating Cash Flow
-10.7M
↓ 3.78%
Investing Cash Flow
-174.0K
↑ 9.43%
Financing Cash Flow
38.0M
↑ 60.76%
Q4 FY22Q/Q Change
Operating Cash Flow
-7.9M
↓ 25.75%
Investing Cash Flow
-59.0K
↓ 66.09%
Financing Cash Flow
265.0K
↓ 99.3%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.8M
↓ 40.1%
Investing Cash Flow
-4.4M
↑ 7293.22%
Financing Cash Flow
-1.4M
↓ 624.15%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.6M
↑ 102.56%
Investing Cash Flow
4.2M
↓ 195.8%
Financing Cash Flow
19.4M
↓ 1499.42%

Technicals Summary

Sell

Neutral

Buy

Dariohealth Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dariohealth Corp
Dariohealth Corp
13.99%
35.83%
-55.83%
-90.65%
-90.69%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.03%
13.08%
-0.38%
-7.92%
96.79%
Agilent Technologies Inc.
Agilent Technologies Inc.
-2.21%
29.14%
6.66%
7.13%
84.4%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-1.02%
26.1%
5.58%
23.6%
111.77%
Danaher Corp.
Danaher Corp.
1.85%
26.39%
3.98%
-3.96%
88.86%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.12%
14.71%
20.71%
-1.02%
72.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dariohealth Corp
Dariohealth Corp
NA
NA
0.0
-1.37
-0.86
-0.33
NA
2.14
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.03
49.03
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.89
32.89
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.35
37.35
2.81
21.53
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
45.86
45.86
3.13
7.63
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.18
32.18
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dariohealth Corp
Dariohealth Corp
Buy
$43.9M
-90.69%
NA
-292.0%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.1B
96.79%
49.03
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$40.8B
84.4%
32.89
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$220.4B
111.77%
37.35
13.99%
Danaher Corp.
Danaher Corp.
Buy
$185.5B
88.86%
45.86
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.8B
72.0%
32.18
9.06%

Institutional Holdings

  • Nantahala Capital Management, LLC

    16.82%

  • Appian WAY Asset Management

    4.76%

  • Y.D. More Investments Ltd

    4.64%

  • Phoenix Holdings Ltd

    4.25%

  • Clal Insurance Enterprises Holdings Ltd

    3.15%

  • Vanguard Group Inc

    1.31%

Corporate Announcements

  • Dariohealth Corp Earnings

    Dariohealth Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.

Organization
Dariohealth Corp
Employees
276
CEO
Mr. Erez Raphael
Industry
Health Technology

Discover More

FAQs